跳到正文
原文
Medical Xpress·· 29 天前精选AI 评分66

分子胶 RPT04402 稳定 PP2A,临床前研究抑制非小细胞肺癌与子宫癌肿瘤生长

'Molecular glue' stabilizes protein that inhibits development of non–small cell lung cancer and uterine cancer

AI 导读

密歇根大学两项研究显示,分子胶 RPT04402 可稳定 PP2A 复合物,在 KRAS 突变非小细胞肺癌细胞、小鼠模型以及子宫癌小鼠和患者来源肿瘤模型中抑制肿瘤生长,两项研究分别发表于 Journal of Clinical Investigation 和 Science Translational Medicine。

推荐理由

两项临床前研究展示用分子胶稳定 PP2A 的思路,并为 KRAS 突变肺癌的耐药提供一种解释。

正文
'Molecular glue' stabilizes protein that inhibits development of non–small cell lung cancer and uterine cancer
RPT0440 enantiomers present distinct affinity binding the same pocket. Credit: Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.ady4852

Protein phosphatase 2A plays a central role in controlling many cell signaling pathways, which are frequently disrupted during tumor development and growth.

PP2A is made up of three proteins that must bind to each other for it to function properly and suppress tumors.

The inability of PP2A to assemble is commonly seen in lung, uterine, prostate and liver cancer.

In two studies, University of Michigan researchers have found that targeting PP2A using a 'molecular glue' that helps the protein to retain its structure can help suppress the growth of cancer cells.

Inhibiting tumor growth in non–small cell lung cancer

Lung cancer is the second most common cancer and the leading cause of cancer death in the United States.

Over 80% of lung cancers are non–small cell lung cancers, in which tumor cells are larger and grow more slowly than those in small cell lung cancer.

Many gene mutations are associated with non–small cell lung cancer, including the gene KRAS, which is important for cell growth and division and is mutated in 30% of cases.

Patients with tumors that have these mutations have shorter survival times and often become resistant to therapies.

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found that targeting PP2A with the molecular glue RPT04402 can help treat non–small cell lung cancers that have KRAS mutations.

"There are several FDA-approved drugs that target KRAS in pancreatic, colon and lung cancer," said Goutham Narla, Louis Newburgh research professor of internal medicine and member of Rogel Cancer Center.

"Although they work well, tumor cells gain resistance after a short period of time."

Using cell lines of non–small cell lung cancers with KRAS mutations, the team showed that anticancer drugs adagrasib and trametinib destabilized PP2A.

This finding could explain why patients eventually become resistant to these therapies. However, when RPT04402 was added, the PP2A complex stabilized and led to cancer cell death.

The researchers confirmed these findings in mouse models and found that the molecular glue caused tumors to shrink.

The combination of adagrasib or trametinib with RPT04402 delayed resistance and increased the treatment effectiveness to over 150 days in mice.

"Although we tested several cell lines and animal models, we don't know whether this combination will work in every case of non–small cell lung cancer," Narla said.

"Our findings represent a new approach to treat up to 20%–30% of all non–small cell lung cancer cases."

The team plans to start clinical trials in collaboration with Spring Works Therapeutics and Merck.

They also hope to extend this study to include other KRAS-mutant tumors and evaluate whether the drug combination works in pancreatic and colon cancers.

Molecular glue RPT04402 may benefit patients with high-grade uterine cancer

The incidence and mortality rates of uterine cancer have been steadily increasing, specifically for aggressive high-grade types.

Uterine cancer is now the most common cancer of the female reproductive system and the deadliest gynecological malignancy.

The common treatment methods include surgery and immunotherapy. However, most high-grade uterine cancer patients either do not respond to treatment or their tumors recur.

Researchers have found that recurrent PP2A mutations drive the development of aggressive uterine cancer.

In a study published in Science Translational Medicine, U-M researchers reported that RPT04402 can restore PP2A's ability to suppress the growth of uterine cancer cells.

Using both mouse uterine cancer cells and patient-derived tumor models, the team showed that RPT04402 could reduce tumor growth and size. It did not cause any weight loss or toxicity.

They are interested in extending the work to other cancer types and neurodevelopmental disorders that harbor PP2A mutations.

"To our knowledge, this is the first treatment to directly target a driver of high-grade uterine cancers and we're incredibly excited about bringing this treatment to the patients," said Caitlin O'Connor, research assistant professor of internal medicine.

Publication details

Irene Peris et al., Restoration of PP2A AαB56αC trimer formation by RPT04402 molecular glue in high-grade uterine cancer, Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.ady4852

Journal information: Journal of Clinical Investigation , Science Translational Medicine

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: 'Molecular glue' stabilizes protein that inhibits development of non–small cell lung cancer and uterine cancer (2026, October 22) retrieved 22 October 2026 from https://medicalxpress.com/news/2026-10-molecular-stabilizes-protein-inhibits-nonsmall.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com